Clinical Trials · NCT02638805
Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Intarcia Therapeutics
- Enrollment
- 136
- Start date
- Dec 2015
- Locations
- 36 sites, United States
- Primary endpoint
- Number (percentage) and severity of treatment-emergent adverse events (TEAEs) of nausea and/or vomiting